Welcome to our dedicated page for Bioadaptives news (Ticker: BDPTD), a resource for investors and traders seeking the latest updates and insights on Bioadaptives stock.
BioAdaptives Inc. (BDPTD) pioneers natural health solutions through biotechnology and nutraceutical innovation. This page aggregates official announcements, product developments, and strategic updates directly from the company.
Access timely press releases covering clinical research findings, leadership appointments, and new supplement formulations. Investors and industry professionals will find verified updates on stem cell activation technology, adaptogen-based products, and partnerships advancing cellular regeneration science.
All content undergoes strict editorial review to ensure accuracy and relevance. Bookmark this page for centralized access to BioAdaptives' latest scientific milestones and regulatory filings, helping you make informed decisions based on primary-source information.
BioAdaptives Inc. (OTC: BDPT) has announced successful completion of dosage trials for its weight loss product Zeranovia™. The trial demonstrated significant results, with participants experiencing weight loss of 5-7 pounds per week with minimal side effects.
Key findings include consistent weight loss across participants, with the main side effect being mild gastrointestinal discomfort, manageable through increased water intake or dosage adjustments. All trial subjects requested to proceed to the next phase, demonstrating high satisfaction levels.
Based on these promising results, BioAdaptives is proceeding with dosage adjustments for the next stage of clinical trials, aiming to address the global need for effective and safe weight loss solutions.
BioAdaptives Inc. (OTC: BDPT) has appointed Reed Harris to its Board of Advisors. Harris, currently serving as Senior Vice President of Athlete Development and Marketing at UFC, brings over 40 years of experience in leadership and business management. He is the founder of World Extreme Cagefighting (WEC), which he sold to UFC in 2006 and managed until its 2012 merger.
Harris will collaborate with BioAdaptives' marketing department to launch several new products, including Xcellera, a stem cell activator. Clinical trials have shown Xcellera increases circulating stem cells by 268.8% in 28 days, supporting tissue repair, anti-aging, immune and cardiovascular functions.
BioAdaptives Inc (OTC: BDPT) has appointed Mark Frissora to its Board of Directors. Frissora brings over 40 years of executive leadership experience, notably as Chairman and CEO of Hertz Global Holdings, where he led a comprehensive revitalization that positioned Hertz as the world's fastest rental car company.
At Caesars Entertainment, Frissora orchestrated a global brand relaunch, strengthening the company's position in the gaming industry. His earlier career included roles at General Electric and North American Philips, where he developed expertise in marketing, brand development, and corporate strategy.
BioAdaptives' CEO James Keener expressed confidence that Frissora's experience in transformative leadership and operational excellence will help advance the company's mission of delivering innovative health and wellness solutions.
BioAdaptives Inc. (OTC: BDPT) has received FINRA approval for a dividend distribution to common stock shareholders. The dividend will be payable on January 22, 2025, with an Ex-dividend Date of January 23, 2025. The distribution excludes preferred stockholders.
Shareholders holding stock in certificate or book entry form with the transfer agent will receive confirmation letters for their new stock issuance in book entry form. CEO James Keener expressed gratitude to shareholders for their support and confidence in the company's vision to revolutionize health and wellness. The company continues to focus on developing innovative health solutions and expanding its market presence both domestically and internationally.
BioAdaptives (OTC: BDPT) has launched Xcellara™ Stem Cell Activator, a new supplement designed to enhance stem cell regeneration through a blend of adaptogens, herbs, and beneficial bacteria. The product has been scientifically shown to increase circulating stem cells in humans and animals.
The supplement provides approximately 6 grams of complete protein per 10 grams and is rich in vitamins A, C, E, B-complex, and 62 essential minerals. Key benefits include cardiovascular support, cholesterol management, anti-inflammatory properties, and metabolic health enhancement. The product undergoes rigorous laboratory testing to ensure quality.
BioAdaptives Inc. (OTC: BDPT) has announced a one-for-one stock dividend approved by its Board of Directors. Shareholders will receive one additional share of common stock for each share owned as of the record date, which is projected for the second week of January 2025. The payment will be distributed within 15 days from the Record Date. CEO James Keener emphasized that this dividend aims to acknowledge shareholders' support and enhance stakeholder value.
